Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury Arch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammationNovel Mechanism of Action - selective dipeptidase-1 (DPEP-1) antagonists...

Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide TORONTO, March 30, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval from the Turkish Ministry...

Arch Biopartners Closes Non-Brokered Private Placement TORONTO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...

Empowering Faith Communities to Champion Black Health Equity Amid A Pandemic RICHMOND, Va., Oct. 28, 2020 (GLOBE NEWSWIRE) -- The Balm In Gilead Inc. is a leader in bringing public health and faith communities together to strategically address health disparities in the...

Scholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences Successful demonstration of preclinical in vivo proof-of-concept studies advances collaboration to develop highly specific inhibitors of TGFβ activation for the potential treatment of patients...